In a note put out today, Neuren is one of just 3 ASX-listed healthcare stocks recommended by Ord Minnett.
Their price target is $30.80. Of that, trofinetide is allocated a “modest” value of $10 with NNZ-2591 representing the remaining two thirds of the valuation.
In summary,
NEU stands out as a profitable, self-funding growth company with solid capital adequacy and returns.
In a note put out today, Neuren is one of just 3 ASX-listed...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
-0.140(1.07%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $4.627M | 354.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7585 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 3344 | 2 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |